New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTUBS, UBS, LAZ, LAZ, ED, ED, BLK, BLK, MRK, MRK, T, T, NYX, NYX, CPB, CPB, HES, HES, JNJ, JNJ, INTC, INTC, AA, AA, SAN, SANCapital Link to host a forum
Annual CSR Forum: CSR & IR--Maximizing Shareholder Value will be held in New York on March 13.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 19, 2015
13:10 EDTINTCIntel sees FY15 gross margin about 62%
12:50 EDTINTCIntel rises after FY16 outlook
Subscribe for More Information
12:29 EDTINTCIntel raises dividend to $1.04 per share on an annual basis
Subscribe for More Information
12:27 EDTINTCIntel sees FY16 CapEX $10B plus/minus $500M
12:26 EDTINTCIntel sees FY16 gross margin at 62% plus/minus couple of points
Subscribe for More Information
12:25 EDTINTCIntel sees FY16 revenue growth in the mid-single digits, consensus $57.48B
Subscribe for More Information
11:52 EDTINTCIntel sees Altera as accelerator of 'virtuous cycle'
Subscribe for More Information
11:41 EDTINTCIntel says Cloud is key growth area for Data Center
11:32 EDTINTCIntel says Tabet business is not a growth business
Subscribe for More Information
11:24 EDTINTCIntel targets FY15 revenue $55.2B, consensus $55.25B
Comments from Intel Investor Meeting.
07:43 EDTINTCHouse Energy & Commerce Committee to hold a hearing
The Commerce, Manufacturing and Trade Subcommittee holds a hearing entitled, "The Disrupter Series: The Fast-Evolving Uses & Economic Impacts of Drones" with Joshua Walden, Senior Vice President and General Manager of the New Technology Group at Intel on November 19 at 10:15 am. Webcast Link
06:34 EDTMRKEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
17:21 EDTBLKBlackRock closing down Global Ascent fund, NY Times says
Subscribe for More Information
13:44 EDTINTCBefore the Move: Watch Intel into tomorrow's analyst day
Chipmaker Intel's (INTC) analyst day tomorrow could yield information on numerous company operations, but Jefferies analyst Mark Lipacis cautions investors that the probability for positive surprises appears low given recent spending outlays. BACKGROUND: Intel, one of the largest semiconductor makers in the world, is scheduled to hold an analyst day on Thursday, November 19. Beyond providing forecasts for its various business segments and remarks on the larger computer market, Intel is expected to provide further clarity on several recent stories, including its memory joint venture with Micron (MU), plans to invest heavily in a Chinese production facility and progression towards chips on the 10 nanometer scale. STRONG OUTLOOK, MILD MEETING: Intel's pending acquisition of Altera (ALTR) and its plans to invest as much as $5.5B in a computer memory facility in Dalian, China leave little room for positive surprises at tomorrow's event in regards to 2016 margins, capital expenditures, or shareholder returns, Jefferies analyst Mark Lipacis said in a recent research note. That said, the analyst views Intel's Chinese facility expansion as part of a "brilliant investment strategy that positions Intel as a partner to China" and "keeps the market open" to its microprocessors, perhaps Intel's more famed business segment. Though the two initiatives are certain to push up near-term debt load, Lipacis takes the longer-term view, reminding investors that Intel has shown consistently strong free cash flow over the past decade, leading him to forecast another $13B in 2016. The year may also bring "a number" of other positives for the company, including more data center wins after the Altera tie-up, potentially renewed sales on a cyclical uptick in PC gaming, and even the possibility of an iPhone chip contract, though Lipacis said none of those points look set to be discussed tomorrow. The analyst kept a Buy rating and $38 price target on the shares while reiterating that Thursday's Intel event may have little in store for those expecting eye-grabbing surprises. PRICE ACTION: Shares of Intel have advanced roughly 0.9% to $32.92 Wednesday afternoon. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.
11:33 EDTTSprint announces launch of LTE Plus network
In celebration of the launch of its new LTE Plus network, Sprint (S) is introducing the biggest wireless offer in U.S. history - 50% off the price of most Verizon (VZ), AT&T (T) and T-Mobile (TMUS) rate plans, the company says. New customers can sign up for this offer nationwide Nov. 20 through Jan. 7, 2016. LTE Plus, available today in 77 major markets, takes advantage of Sprint's rich triband spectrum portfolio, and it uses some of the world's most advanced technologies in wireless, such as carrier aggregation and antenna beamforming. Customers who switch get 50 percent off most current rate plan prices from their current carrier. AT&T, T-Mobile and Verizon customers switching to Sprint also can take advantage of iPhone Forever, where they are eligible to upgrade every time a new iPhone launches. Customers must port one line, and can add up to 9 additional lines on the account. Customers must choose from the 50 percent off rate plans available from their current carrier. Cricket and MetroPCS customers also can switch and save 50 percent off their parent company's postpaid rates. 50 percent off pricing remains valid until Jan. 8, 2018, for activations between Nov. 20, 2015, and Jan. 7, 2016.
10:00 EDTLAZOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Apple (AAPL) upgraded to Conviction Buy from Buy at Goldman... BorgWarner (BWA) upgraded to Buy from Neutral at Goldman... Cognex (CGNX) upgraded to Buy from Hold at Canaccord... FARO Technologies (FARO) upgraded to Buy from Hold at Canaccord... Lazard (LAZ) upgraded to Strong Buy from Outperform at Raymond James... LendingClub (LC) upgraded on valuation, positive outlook at Sterne Agee CRT... Middleby (MIDD) upgraded to Outperform from Market Perform at BMO Capital... Perrigo (PRGO) upgraded to Buy from Neutral at B. Riley... RE/MAX Holdings (RMAX) upgraded to Market Perform from Underperform at JMP Securities... Sally Beauty (SBH) upgraded to Buy from Neutral at Goldman... Shopify (SHOP) upgraded to Outperform from Market Perform at Raymond James... TASER (TASR) upgraded to Buy from Neutral at Ladenburg... USG (USG) upgraded to Buy from Neutral at Northcoast.
08:11 EDTJNJ, MRKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
07:33 EDTLAZLazard upgraded to Strong Buy from Outperform at Raymond James
Subscribe for More Information
07:01 EDTMRKThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use